On May 24, 2024, Biocon Ltd announced in an exchange filing that the company had signed an exclusive licensing and supply agreement with Handok to commercialise its vertically integrated, complex drug product, Synthetic Liraglutide. Handok is a speciality pharmaceutical company in South Korea. It is involved in the development and distribution of healthcare solutions to …